Clinical Trials Logo

Nervous System Diseases clinical trials

View clinical trials related to Nervous System Diseases.

Filter by:

NCT ID: NCT06407154 Not yet recruiting - Stroke Clinical Trials

Chronical Illness-related Limitations of the Ability to Cope With Rising Temperatures: an Observational Study, 2nd Wave

CLIMATE-II
Start date: May 15, 2024
Phase:
Study type: Observational

The CLIMATE-II Observational Study examines to what extent chronically ill patients experience adverse health effects because of heat and whether the patients' specific health behavior, somatosensory amplification, risk and benefit perception, self-efficacy, health literacy, degree of urbanisation of the patients' administration district and characteristics of the patients' neighborhood are associated with these effects.

NCT ID: NCT06406127 Recruiting - Breast Cancer Clinical Trials

Effect of Alpha Lipoic Acid on Chemotherapy Induced Neurological Changes in Breast Cancer Patients

Start date: April 1, 2024
Phase: Phase 4
Study type: Interventional

92 female cancer patients, aged from 18 to 75 years old (with a first diagnosis of breast cancer) who will receive Paclitaxel-based chemotherapy (12 weeks) as first line therapy, will be enrolled in the study and will be randomly assigned to either: - Group I: will receive the chemotherapy protocol or - Group II: will receive the chemotherapy protocol plus 600 mg daily dose of Alpha Lipoic Acid for 14 weeks (one week before the start of paclitaxel and continue till one week after the end of paclitaxel). * Blood samples will be withdrawn 2 times (week 1 and week 12) to measure the following: (Stored in -80 C till the end of the study) - Tumor Necrotizing Factor- alpha (TNF-α) by ELISA. - Brain-Derived Neurotrophic Factor (BDNF) by ELISA. * All patients will be subjected to 6 tests/questionnaires (week 1 - week 12 - week 24) to predict the functionality of the brain: - Functional Assessment of Cancer Therapy-Cognitive (FACT-Cog) version 3 - Mini-Cog Test - Mini Mental State Examination (MMSE) - Controlled Oral Word Association Test (COWAT) - Hopkins Verbal Learning Test (HVLT) - Trail Making Test (TMT)

NCT ID: NCT06393465 Not yet recruiting - Clinical trials for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Start date: April 29, 2024
Phase:
Study type: Observational

This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records

NCT ID: NCT06390800 Completed - Clinical trials for Neurological Disorder

Personalized Motor Learning in Primary Care Physiotherapy (TREAT)

Start date: September 6, 2023
Phase:
Study type: Observational

Over the last decade many scientific articles have been published on motor learning in neurological and geriatric rehabilitation. To make the available findings comprehendible and clear for physiotherapists, a card set and website have been developed. The aim of this prospective study is to evaluate the use and experiences of the card set and website designed to aid the physiotherapist in decision making with regards to motor learning. The following research question is central to this evaluation: How are the developed card set and website used and experienced by physiotherapists in primary care during the treatment of patients with neurological or geriatric conditions?

NCT ID: NCT06390748 Completed - Sepsis Clinical Trials

Esmolol in Sepsis Management:Evaluating Immunomodulatory Effects and Impact on Patient Outcomes

Start date: January 1, 2021
Phase: Phase 2
Study type: Interventional

Evaluate the effectiveness of esmolol, a selective β1-adrenergic receptor blocker, in modulating immune responses and improving patient outcomes in sepsis.

NCT ID: NCT06387225 Not yet recruiting - Cardiac Arrest Clinical Trials

Early and Objective Assessment of Neurological Prognosis in Cardiac Arrest Patients

HYPERION-2
Start date: September 1, 2024
Phase:
Study type: Observational

Cerebral lesions are responsible for two thirds of deaths in patients admitted to intensive care following cardiac arrest. Patients with neurological lesions should be the priority target for neuroprotective interventions, which are the cornerstone of post-cardiac arrest care (allowing a reduction in the burden of care for patients without this type of lesion). Furthermore, these interventions must be based on a precise assessment of the severity of these brain lesions: carrying out neuro-protective interventions in patients without brain lesions exposes these patients to unnecessary treatment potentially associated with adverse effects without any possible benefit. However, the early assessment of neurological prognosis, particularly on admission to intensive care, is an area where there is little research and where it is not possible to obtain a precise and reproducible assessment. Several tools can be used to assess this prognosis at an early stage: anamnesis and characteristics of the cardiac arrest and the patient's comorbidities, imaging, electrophysiology and biomarkers. To assess the predictive value of early biomarker testing in patients resuscitated after cardiac arrest, whatever the cause, the investigators plan to conduct a prospective observational multicentre trial. It is important to bear in mind that the aim of this study is not to assess the long-term prognosis of patients suffering cardiac arrest in order to take measures to limit or discontinue active therapies, but simply to provide a reliable tool, simple and quick to use, in order to be able to identify a sub-population of patients who should be the subject of preferential neuro-protection measures, and conversely to simplify management (moderate temperature control, early cessation of sedation, early extubation) for patients with no neurological lesions.

NCT ID: NCT06382467 Not yet recruiting - Neurologic Disorder Clinical Trials

Comparison of Remimazolam and Propofol Combination vs. Propofol in IOM

Start date: May 2024
Phase: Phase 4
Study type: Interventional

This study aims to compare total intravenous anesthetic agents: combined remimazolam and propofol vs. propofol monotherapy. The comparison parameters are intraoperative hypotension, patient's involuntary movement, neurophysiological monitoring quality, onset time, recovery time, and postoperative rescue anti-emetics requirements.

NCT ID: NCT06378372 Not yet recruiting - Dementia Clinical Trials

How Does Pianistic Musical Training Influence the Development of Alzheimer's Disease?

Start date: June 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to learn about and describe how pianistic training influences the development of Alzheimer's disease. The key question is: Can pianistic practice influence the development of Alzheimer's disease? Participants will receive piano lessons for 4 weeks (20 sessions) and we will evaluate the evolution of the different parameters described by the tests carried out.

NCT ID: NCT06368024 Completed - Healthy Clinical Trials

Establishment of Delphi-MD Safety Performance and Reliability

Start date: November 28, 2023
Phase:
Study type: Observational

A retrospective analysis of collected datasets. In this study we aim to establish Delphi-MD's safety and performance reliability for assessment and monitoring of Transcranial Magnetic Stimulation (TMS) Evoked Potentials (TEPs) as neurophysiological measurements.

NCT ID: NCT06362161 Not yet recruiting - Clinical trials for Functional Neurological Disorder

Establishment of an Interdisciplinary Functional Neurological Disorder (FND) Treatment Program and Development of a Clinical Care Pathway for FND

Start date: May 1, 2024
Phase:
Study type: Observational [Patient Registry]

The purpose of this study is to help providers develop an interdisciplinary treatment pathway for functional neurological disorder (FND) at University of Alabama at Birmingham (UAB), and will involve psychiatry, speech therapy, physical therapy, and occupational therapy. The study will also help providers to evaluate the treatment pathway and publish results regarding the process and outcomes.